TickerTalks
Browse all tickers →
TickerTalks›$CVS
CVCVS

CVS Health Corp.

$CVS·$114B·Medical - Healthcare Plans·Healthcare
$87.23-0.7%YTD+10.8%1Y+16.2%
Price updated 37m ago·X counts updated 2d ago
CVCVS
$CVSCVS Health Corp.
$87.23-0.71%194 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $CVS on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

194X posts · last 7 days
Sep 11Sep 27
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $CVS's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 76% of tracked names.

Mixed sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-09-15

CVS commentary that managed-care medical cost trends remain elevated pressures the sector (UNH, OSCR down), but a value-oriented long argues low expectations create asymmetric upside with wave-structure suggesting completion. Aetna/CVS coverage-access confusion around RVMD's drug adds a small reputational drag.

Read what X is saying about $CVS

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $CVS — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-09-28

The move is getting stronger, with heavier trading behind it.

CVS Health is up 12% YTD grinding through elevated medical cost trends — real beats, real cash flow, real value setup.

CVS Health is the diversified pharmacy, PBM (Caremark) and Aetna managed-care conglomerate — one of the largest healthcare franchises in the US. It's up 12% year-to-date and the tape is at 48% of the 52-week range, waiting on the November 4 print.

  • The earnings cadence is unusually strong: last quarter EPS printed $2.58 vs $1.87 estimated — a 38% beat and the fourth double-digit beat in a row — and analysts see revenue moving from ~$417B this year to $475B by 2029 with EPS climbing from $8.02 to $10.85.
  • The valuation is friendly on the cash flow: 44x trailing PE (elevated on restructured earnings) but 0.32x sales and 5.7% free cash flow yield — cheap on FCF metrics even if the trailing PE looks expensive.
  • The insider tape is empty on transactions but the Q2 print was a major re-rating catalyst — the market is pricing whether Q3 continues the operating-leverage trajectory.

November 4 Q3 earnings and any color on Q4 Medicare Advantage medical-cost trend plus Caremark 2027 renewal season decides the next leg — a re-affirmed FY guide with clean MCT restarts the tape; a UNH-style Medicare-utilization surprise or a Caremark retention concern is what turns acceleration into a real digestion.

Agrees with X sentimentAgrees with the low-expectations-asymmetric-upside framing — CVS has genuinely reset expectations lower and then repeatedly outperformed, and the wave-structure-completion read is directionally right — the elevated medical-cost trend is real but the ~38% Q2 beat says the operating team is on top of it.

What to watch: November 4 Q3 earnings — Q4 Medicare Advantage medical-cost trend, Caremark 2027 renewal season, and Aetna margin trajectory; a re-affirmed FY with clean MCT restarts the tape, a UNH-style utilization surprise or Caremark retention concern turns acceleration into digestion.

On the calendar: 2026-11-04 — Q3 earnings

Read the AI verdict on $CVS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Integrated healthcare company operating pharmacies, pharmacy benefit management, health insurance, and MinuteClinic locations across the U.S.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Plans sits in its cycle right now — and what that implies for $CVS.

Medical - Healthcare Plans · Healthcare

Medicaid redeterminations (post-COVID eligibility reviews) have reduced Medicaid enrollment ~15M from peak, improving commercial insurance mix at managed care organizations; Medicare Advantage star ratings and benchmark rate adjustments are the primary 2026 earnings variable. MLR creep from utilization recovery and GLP-1 pharmacy costs are the key margin headwinds.

What this means for $CVS

Partial — Integrated healthcare company operating pharmacies, pharmacy benefit management, health insurance, and MinuteClinic locations across the U.S.

Top industry ETF

$IHFiShares U.S. Healthcare Providers ETF
+15.9%YTD
+13.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
44.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
2.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
1.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
5.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
3.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
13.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$2.58$1.87+38.0%
Q1 2026May 6, 2026$2.57$2.21+16.3%
Q4 2025Feb 10, 2026$1.09$1.00+9.0%
Q3 2025Oct 29, 2025$1.60$1.37+16.8%
Next earningsWed, Nov 4·consensus EPS $1.62

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$100.4B+6.2%15.6%4.7%$2.31$3.4B
Q4 FY25$105.7B+8.2%12.8%2.0%$2.32$2.6B
Q3 FY25$102.9B+7.8%13.4%-3.1%$-3.13$98.0M
Q2 FY25$98.9B+8.4%13.7%2.4%$0.81$1.3B

Forward consensus

5-year forecast · up to 17 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$416.5B$412.9B – $421.5B$8.02$7.94 – $8.1517
FY27$429.6B$423.1B – $435.1B$8.51$8.44 – $8.9217
FY28$449.1B$425.2B – $477.5B$9.70$8.92 – $10.8617
FY29$474.8B$462.1B – $490.7B$10.85$10.47 – $11.3213
FY30$491.9B$478.8B – $508.4B$11.75$11.34 – $12.268

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.45%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-9.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+0.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 1.3B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.585-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMay 21Larry RobbinsDirector748.5K sh$56.7MSellMay 20Larry RobbinsDirector1.0M sh$95.5MSellMay 19Larry RobbinsDirector2.0M sh$187.3MSellMay 8Tilak MandadiEVP, Chief Exp & Tech Officer69.6K sh$6.2M
+ 17 other (12 awards · 3 inkinds · 2 returns) in window

See when $CVS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeAug 178-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

CVS Health (CVS) filed an 8-K under Items 5.02, 7.01, and 9.01, disclosing an executive officer or director change and a Regulation FD disclosure effective August 13, 2026. No specific names or details were available in the excerpt. CVS Health is the largest pharmacy chain in the U.S. and a major pharmacy benefit manager and health insurer.

S-3ASRAuto-shelf registrationMay 22S-3ASR
AI summary

CVS Health Corporation filed an automatic shelf registration statement (S-3ASR) on May 22, 2026, enabling the company to offer and sell unspecified amounts of various securities on a delayed or continuous basis. As a large accelerated filer, CVS is eligible for this expedited registration process that becomes effective immediately upon filing without SEC staff review. The registration provides financial flexibility to access capital markets efficiently for potential debt, equity, or hybrid securities offerings. No specific offering terms, size, or timing are determined at the time of filing.

8-KOfficer or director changeMay 188-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

CVS Health held its 2026 Annual Meeting on May 14, 2026, at which stockholders approved the new 2026 Incentive Compensation Plan (ICP) to replace the expiring 2017 ICP, enabling ongoing equity- and cash-based compensation awards for employees and executives. The meeting also included director elections and other routine corporate matters, with vote tallies included in the full filing. Item 5.02 discloses an officer or director change in connection with the annual meeting. The new 2026 ICP is necessary for CVS to continue making equity grants in the ordinary course of business.

+ 13 other (2 13Gs · 2 13Fs · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

CVS Health (CVS) Falls More Steeply Than Broader Market: What Investors Need to Knowzacks.com·20h agoCVS Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CVS Health Corporation - CVSbusinesswire.com·1d agoDid CVS Health Corporation Insiders Breach their Fiduciary Duties to Shareholders?gurufocus.com·4d agoDid CVS Health Corporation Insiders Breach their Fiduciary Duties to Shareholders?prnewswire.com·4d agoCVS Health Stock Still Looks Good Even If Health Cost Woes Materializeseekingalpha.com·4d ago

More in Medical - Healthcare Plans

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$OSCR$UNH$CI$CLOV$CNC$ALHC$HUM$MOH
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport